Methods of Detecting reduced susceptibility to glycopeptides in S

Slides:



Advertisements
Similar presentations
Kirby-Bauer disk diffusion Testing skill based learning
Advertisements

Direct Sensitivity Performed when : * Gram stain shows large number of one type of reaction * To get quick result for serious cases * Used only.
Development of an agar dilution susceptibility testing method for Fusobacterium mecrophorum M. Wootton, V. Hall, T. Morris, R. A. Howe Introduction Fusobacterium.
Susceptibility Testing Anaerobes
BSAC ANTIMICROBIAL SUSCEPTIBILITY TESTING & RESISTANCE MEETING CARDIFF – 13 TH MAY, 2010 Vancomycin Susceptibility Testing in Staphylococcus aureus: Clinical.
British Society for Antimicrobial Chemotherapy Symposium Resistance and treatment issues in Blood Stream Infection: S.aureus Alasdair MacGowan BCARE University.
Figure 1: Differential in MICs for common C. difficile ribotypes Introduction Clostridium difficile has been identified as the primary cause of nosocomial.
Improved growth of Vancomycin resistant Enterococci on ChromID™ VRE agar by incubation in 5% CO 2 Varuna Navaratne, Sydney Bell and Jeanette Pham SEALS.
Antimicrobial Susceptibility Testing – Part II
BSAC Standardised Disc Susceptibility Test User Group Day. Royal College of Physicians, London. 8 June 2007 Susceptibility testing of mucoid Pseudomonas.
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
The Use of Cefoxitin for the Determination of Methicillin Resistance in Staphylococci John D. Perry Microbiology Department Freeman Hospital Newcastle.
PHT 381 Lab # 7. Antibiotic Sensitivity Testing Antibiotic sensitivity testing is used to determine the susceptibility of the microorganism to various.
TITLE Mannitol Salt Agar-Cefoxitin Combination as a screening Medium for Methicillin-Resistant Staphylocuccus aureus.
Susceptibility of Drug Resistant Acinetobacter baumanii (DRAB) to a stabilized aqueous allicin extract from garlic (AB1000 ). Researchers’/Presenters’
ANTIBIOTIC SUSCEPTIBILITY TESTING AND DRUG RESISTANCE Rashmi S.
Vitek 2 – A User Experience.
Melioidosis: Current Diagnostic Approach and Role in Clinical practice Rob Baird Royal Darwin Hospital.
IN THE NAME OF ALLAH ALMIGHTY THE MOST COMPASSIONATE THE MERCIFUL.
PHT 416 Lab no 10 Minimum Inhibitory Concentration [MIC]
KIRBY – BAUER MINIMUM INHIBITORY CONCENTRATION MINIMUM BACTERIOCIDAL CONCENTRATION.
ANTIBIOTICS SUSCEPTIBILITY TESTING
Methods for detecting resistance Goal: To determine whether organism expresses resistances to agents potentially used for therapy Designed to determine.
IN THE NAME OF ALLAH ALMIGHTY THE MOST COMPASSIONATE THE MERCIFUL.
Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus Methods of Detecting reduced susceptibility to glycopeptides in S. aureus BSAC.
Susceptibility of Drug Resistant Acinetobacter baumanii (DRAB) to a stabilized aqueous allicin extract from garlic (AB1000 ). Researchers’/Presenters’
Antibiotic sensitivity
Antibiotics (anti-microbials)
Etest Etest is a quantitative technique for: * Determination of MIC of antibiotic * Detection of resistance It comprises a gradient.
Lab: 6 ANTIBIOTIC SENSITIVITY TESTING
Lab # 1. Antimicrobial Therapy  Natural antibiotic agents:  Produced by microorganisms:  Penicillium notatum – penicillin  Semi-synthetic antibiotic.
MRSA, ESBLs and Carbapenem Resistance
Quality Control of Antimicrobial Susceptibility Tests
Comprised of Blood Agar and CHROMagarTM Orientation using WASPLabTM
corresponding author’:
Angelo Berchieri Jr  Clinical Microbiology and Infection 
Antimicrobial Susceptibility Testing (AST)
The Plot Thickens.
Antimicrobial susceptibility testing of colistin – evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli,
Disc susceptibility testing for Burkholderia cepacia complex
D th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC Evaluation of a Rapid PBP2’ Agglutination.
D-739/181 50th ICAAC Sept , 2010 Boston
D-735/178 50th ICAAC Sept , 2010 Boston
F th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC The Activity of RTA-3, a Novel Antimicrobial.
Antibiotic Susceptibility Testing
In the Name of GOD.
Vancomycin-intermediate Staphylococcus aureus isolates are attenuated for virulence when compared with susceptible progenitors  D.R. Cameron, Y.-H. Lin,
Antibiogram By:Dr. S. S. Khoramrooz In the name of God
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with.
In vitro activity of cefpirome and vancomycin in combination against gentamicin- susceptible and gentamicin-resistant Staphylococcus aureus  A. Carricajo,
C th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, USA Emergence of VIM-2 Metallo--lactamase.
Angelo Berchieri Jr  Clinical Microbiology and Infection 
W. Witte, B. Pasemann, C. Cuny  Clinical Microbiology and Infection 
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with.
Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals  C. Nonhoff, O. Denis,
C. -J. Soussy, J. Nguyen, F. Goldstein, H. Dabernat, A. Andremont, R
False synergy between vancomycin and β-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods 
Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream.
MIC distribution and inoculum effect of LY333328: a study of vancomycin-susceptible and VanA-type and VanC-type enterococci obtained from intensive care.
Antibiotic susceptibility testing
Can β-lactams be re-engineered to beat MRSA?
Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals  G.L. Cartolano,
P.M. Hawkey  Clinical Microbiology and Infection 
Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan 
Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals  M.E. Reverdy, S. Jarraud, S. Bohin-Duhreux, E.
Can pharmacokinetic–pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance?  P. Courvalin  Clinical Microbiology and.
Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents    Clinical Microbiology and Infection  Volume.
Phenotypic consequences of the most common rpoB mutants.
Recommended scheme for determination of heteroresistance and interpretation criteria. Recommended scheme for determination of heteroresistance and interpretation.
Example of population analysis profile curves for vancomycin-susceptible and heterogeneous vancomycin-intermediate S. aureus strains. Example of population.
Presentation transcript:

BSAC Antimicrobial Susceptibility Testing & resistance Meeting, 25th October 2010 Methods of Detecting reduced susceptibility to glycopeptides in S. aureus Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus Presenter: Mandy Wootton

Phenotype Glycopeptide Resistant Staphylococcus aureus GRSA vanA gene present, MIC VAN >32mg/L Glycopeptide Intermediate Staphylococcus aureus GISA homogeneous resistance, mechanism unknown - MIC VAN ~4/8mg/L (Mu50) heterogeneous-Glycopeptide Intermediate Staphylococcus aureus hGISA heterogeneous resistance, mechanism unknown - MIC VAN ~1.5/4mg/L (Mu3). Precursor to GISA Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

Prevalence GRSA GISA/hGISA < 30 world wide None in UK UK prevalence: <1% (EARSS) 6064 isolates (1 Intermediate) MIC 0% (2001-6 BSAC Bacteraemia) 615 isolates Cardiff: 0.8% 669 MRSA PHX, disc, MHA5T, PAP-AUC Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

BSAC Breakpoints GSSA hGISA GISA MIC <0.25 0.5 1 2 4 8 16 GSSA hGISA GISA Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

EUCAST Breakpoints GSSA hGISA GISA MIC <0.25 0.5 1 2 4 8 16 GSSA hGISA GISA Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

Disc Diffusion 1 ISA with 1:10 of 0.5 McFarland inoculum 5g Vancomycin disc Incubation at 35-37°C for 18-20h Interpretive Criteria: Resistance - 14mm Susceptible - 15mm GRSA: Detected GISA: NOT Reliably Detected hGISA: NOT Detected Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

Disc Diffusion 2 ISA with 1:10 of 0.5 McFarland inoculum 5g, 30g Vancomycin disc 5g, 10g, 20g, 30g Teicoplanin Incubation at 35-37°C for 18-20h Separation of phenotypes Low concn discs of V and T differentiate GISA & GSSA None accurate for ID of hGISA Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

MIC Determination 1 GRSA Detected GISA Mostly Detected Standard Etest 0.5 McFarland on ISA, 18-20h BPs 2 (S)/ >2 (I/R) GRSA Detected GISA Mostly Detected hGISA mostly missed MIC <0.25 0.5 1 2 4 8 16 GSSA hGISA GISA Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

MIC Determination 2 Automated (PHX) Repeat 1 MRSA/GSSA x22 GSSA x10 hGISA x10 GISA x10 Some GISA & hGISA identified Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

Summary Disc MIC (Etest & automated) Detects GRSA (vanA) Some detection of GISA No reliable detection of hGISA MIC (Etest & automated) Detects GRSA Detects some GISA Detects few hGISA Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

Macro Etest Interpretative Criteria: (NOT MICs) 2 McF inoculum Brain Heart Infusion 48h incubation at 35-37°C in air Interpretative Criteria: (NOT MICs) GISA or hGISA if 8mg/L plus 8mg/L Vancomycin + Teicoplanin or 12mg Teicoplanin alone. Detects most hGISA and GISA No distinction between GISA and hGISA 2% false positive Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

GRD Etest 0.5 McFarland inoculum Mueller Hinton + blood 48h incubation at 35-37°C in air Reading at 24h and 48h Interpretive criteria: GISA or hGISA if VA or TP 8mg/L GISA if GRD+ and standard VA MIC 4mg/L hGISA if GRD+ and standard VA MIC <4mg/L Detects all GISA, majority at 24h Detects most hGISA and GISA 2% false positives Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

Screening Agar 1 MHA5T Detects Most GISA MHA5T Detects Most hGISA Mueller Hinton Agar + 5mg/L TP (MHA5T) 10ul of 0.5 McF inoculum 48h Incubation at 35-37°C in air Interpretive criteria: hGISA or GISA if ≥1 cols after 48hr Brain Heart Infusion Agar + 6mg/L VA (BHI6V) 10μl of 0.5McF inoculum 24h Incubation at 35-37°C in air hGISA or GISA if ≥2 cols after 24hr Multi-centre study 12 labs (Europe & US) 48 strains 3 method * MHA5T: false positives reduced when 2 cols at 48h used MHA5T Detects Most GISA MHA5T Detects Most hGISA Up to 24% false positives Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

Population Analysis Profile – Area Under Curve 1 “Gold Standard” 2 plates of BHIA + 0, 0.5, 1, 2, 2.5 & 4mg/L VA Overnight cultures of test organism and Mu3 in TSB - diluted 1:10-3, 1:10-6 Incubation at 35-37°C in air for 48hrs 106 / 103 106 / 103 106 / 103 103 / N 103 / N 103 / N Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus

PAP-AUC 2 Log viable count vs. VA concn graph Ratio = AUC of test isolate/AUC of Mu3 PAP-AUC ratio criteria: GSSA < 0.9 hGISA 0.9 - 1.29 GISA  1.3 Methods of Detecting Reduced Susceptibility to Glycopeptides in S. aureus